Point72 Asset Management
CRVS icon

Point72 Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Point72 Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,875,000
Closed -$22.1M – 3890
2025
Q4 		$22.1M Sell
2,875,000
-3,579,274
-55% -$28.2M 0.02% 816
2025
Q3 		$47.6M Sell
6,454,274
-588,099
-8% -$3.01M 0.08% 279
2025
Q2 		$28.2M Buy
7,042,373
+4,254,742
+153% +$15.5M 0.06% 386
2025
Q1 		$8.86M Sell
2,787,631
-242,380
-8% -$1.14M 0.02% 728
2024
Q4 		$16.2M Sell
3,030,011
-2,532,718
-46% -$18.9M 0.04% 531
2024
Q3 		$29.4M Sell
5,562,729
-401,781
-7% -$1.44M 0.07% 310
2024
Q2 		$10.9M Buy
+5,964,510
New +$11.1M 0.03% 578
2022
Q2 		– Sell
-745,000
Closed -$1.22M – 1434
2022
Q1 		$1.22M Sell
745,000
-50,000
-6% -$91.5K ﹤0.01% 935
2021
Q4 		$1.92M Buy
795,000
+220,000
+38% +$853K 0.01% 827
2021
Q3 		$2.78M Buy
+575,000
New +$1.7M 0.01% 753
2017
Q4 		– Sell
-195,034
Closed -$3.11M – 924
2017
Q3 		$3.11M Sell
195,034
-37,349
-16% -$517K 0.01% 617
2017
Q2 		$2.81M Sell
232,383
-175,894
-43% -$1.88M 0.02% 596
2017
Q1 		$8.48M Buy
+408,277
New +$6.4M 0.05% 431

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management's CRVS Position: Q1 2026 in Review

Point72 Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 2,875,000 shares — an estimated $22.1M sold.

Point72 Asset Management first reported a position in CRVS in Q1 2017 and held it in 13 quarters. The position peaked at $47.6M in Q3 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Point72 Asset Management reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 2,875,000 Corvus Pharmaceuticals shares in Q1 2026, an estimated $22.1M.
  • Point72 Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2017 and held it in 13 quarters.
  • Point72 Asset Management's Corvus Pharmaceuticals position peaked at $47.6M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.